

REVIEW ARTICLE

Computational Chemistry: A game-changer in the drug discovery field

Nameer Mazin Zeki¹, Karam M. Z. Othman², Yasser Fakri Mustafa^{3,*}

¹ Department of Pharmacology, College of Medicine, Ninevah University, Mosul, 41001, Iraq

² Department of Cyber Security and Cloud Computing Technology Engineering, Technical Engineering College / Mosul, Northern Technical University, Mosul, 41001, Iraq

³ Department of Pharmaceutical Chemistry, College of Pharmacy, University of Mosul, Mosul, 41001, Iraq

*Corresponding author: Yasser Fakri Mustafa, Dr.yassermustafa@uomosul.edu.iq, <https://orcid.org/0000-0002-0926-7428>

ABSTRACT

The greater development in the computational tools and the presence of a huge number of established chemical libraries emerge the inquiry about the ability to integrate the computational techniques in the drug discovery process. This review emphasizes the role of computational tools and software to accelerate the steps in the drug discovery pipeline. The data were gathered from the trendiest research articles and reviews that were indexed in the well-established scholarly search engines. Different vital techniques, such as virtual screening, pharmacophore modeling, molecular docking, molecular dynamic simulations, and quantitative structure activity relationship, are widely employed for target recognition, lead refining, and forecasting binding behavior at the atomic level. The advancement in artificial cognitive computing software significantly expanded the capabilities for rapid analysis of substantial data sets and the generation of toxicity and bioactivity predictive models of drugs. The contributions of these software tools tackled global problems, like drug repurposing during the coronavirus outbreak, and the direction toward personalized medicaments highlight their crucial role in the swift discovery of new treatments. In addition, computational tools are widely employed to enhance the drug formulations, which leads to discovering drugs with optimum pharmacokinetic and toxicity profiles. The difficulties in analyzing the multi-target binding behaviors and the limited success rates of the generated candidates in the experimental validations were the main existing limitations. However, the steep development in the field of artificial intelligence and the hybrid biochemical-computational approaches provided promising horizons to tackle these limitations. Chemical computational tools significantly affect the future of pharmaceutical research by boosting the drug discovery process toward affordable and efficient medicaments.

Keywords: computational chemistry; docking; drug discovery; molecular dynamic; pharmacophore

ARTICLE INFO

Received: 4 January 2025

Accepted: 7 February 2025

Available online: 12 February 2025

COPYRIGHT

Copyright © 2025 by author(s).

Applied Chemical Engineering is published by Arts and Science Press Pte. Ltd. This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY 4.0).

<https://creativecommons.org/licenses/by/4.0/>

1. Introduction

Drug discovery is a budget-draining and time intensive process that entails the investigation of academic knowledge, clinical trials, and regulatory authorization to ensure the safety and effectiveness of the new medications. The process is protracted and may extend over many years, with no absolute guarantee for success, as a wide range of candidates may not be able to complete their journey toward the pharmacy shelves^[1]. Notwithstanding the obstacles of drug discovery, it is a vital aspect of the healthcare sector since it generates medications that can eradicate diseases, alleviate symptoms, or improve medical conditions^[2,3]. Antibiotics, for instance, altered the way infectious diseases are treated forever, and recent advances in

cancer immunotherapy have given hope patients whose diseases were thought to have no possibility of remission^[4,5]. Typical steps in the drug discovery process include validating the target, finding the lead compounds, refining and optimization of these compounds, and finally, moving on to preclinical research and clinical trials^[6].

The drug discovery pipeline is presently experiencing significant transformations and facing four primary challenges. First, the progress in genomes and structure-based methodologies has led to a decrease in the accessibility of feasible pharmacological targets^[7]. Second, there is an increasing emphasis on maximizing the return on investment throughout the entire pharmaceutical research process^[8]. Third, there is a growing emphasis on ensuring safety, effectiveness, and pharmacokinetics in the early stages of lead discovery^[9]. Fourth, the transition from conventional combinatorial chemistry to more focused and strategic diversification techniques^[10,11].

Computational chemistry is a branch of chemistry that leverages computer simulation to solve complex chemical problems. It plays a crucial role in the molecular-level analysis of biological systems by focusing on an understanding of small molecules, drugs, and complex molecular systems, such as DNA, proteins, and other macromolec^[12,13]. The drug discovery process is a complex interdisciplinary endeavor that often combines principles from chemistry, biology, and pharmacology^[14]. By employing computational tools, researchers can predict the molecular attributes and unmask potential drug candidates more efficiently^[15,16]. Furthermore, these tools will reduce the time and resources typically required for experimental testing. This requires close collaboration between medical scientists and researchers with expertise in multiple disciplinary areas^[17].

This review aims to explore the crucial role of computational chemistry in accelerating the drug discovery process. It provides an overview of the evolution and application of computer-based tools in predicting new drug candidates, with examples of modern tools and techniques. Furthermore, the review discusses the impact of computational methods on drug discovery and offers insights into future perspective in this rapidly advancing field.

2. Drug discovery strategies

There are numerous and diverse strategies to discover new drug candidates. Chemical scientists and those interested in this field actively search for sources of medically related compounds in every region of the world. Generally, the strategies of drug discovery can be divided into traditional ones, those that depend on natural product screening and serendipitous discoveries, and modern or computer-based strategies^[18,19].

2.1. Traditional drug discovery process

In the early stage of the drug discovery process, potential lead compounds are generally identified through high-throughput screening of a large compendium of synthesized or natural compounds^[20,21]. This process starts by exploring thousands to millions of chemical frameworks to identify ones that showed desired biological activity; these are called the lead compounds. Once lead compounds are characterized, their structural frameworks are optimized to enhance their binding affinity and selectivity for their target macromolecules^[22,23]. Importantly, these lead compounds must exhibit acceptable selectivity and specificity towards their target macromolecules while maintaining no affinity or activity towards other targets. Sensitivity issues are also crucial, requiring that these leads have significant activity at small doses to minimize their side effects as much as possible^[24,25]. Additionally, these compounds must have eligible pharmacokinetic properties, such as a suitable elimination rate and plasma half-life, to ensure applicable drug administration. Other frameworks, those that failed to fulfill the requirements, were filtered out^[26,27]. These steps are outlined in **Figure 1**.




Figure 1. Traditional drug discovery process.

Many challenges are encountered in the traditional drug discovery process; these include time, effort consumption, elevated costs, and poor success probability^[28]. Many of the explored frameworks may fail during lead optimization or investigational phases throughout the process, owing to their bioavailability, specificity, or their unfavorable pharmacokinetics^[29,30]. Furthermore, this process depends mainly on the trial-and-error approaches, which can ultimately lead to inefficiencies. Therefore, it has become important to employ the step revolution in computational programs and tools to solve these encountered issues^[31,32].

2.2. Role of computational chemistry

There is a wealth of challenges associated with the discovery and optimization of lead pharmaceuticals, from understanding disease biology to navigating the human use landscape^[33,34]. Moreover, the process is costly and yields uncertain outcomes. New experimental techniques and tools, along with computational methods, are reshaping pharmaceutical drug discovery. The field of computational chemistry is a critical one in the drug discovery space^[35,36]. These methods are broadly applicable to understanding and quantifying the behavior of biomolecular matter, changes to the properties of molecular matter in response to chemical modification, and how matter interacts^[37]. In other words, computational methods are vital for understanding the chemistry that underpins biological behavior and how to leverage that knowledge for therapeutic benefit^[38,39]. The field is now comprised of many scientific disciplines collaborating to understand how physical chemistry and chemical biology principles operate in concert to drive biological behavior^[40,41].

3. Fundamentals of computational chemistry

Computational chemistry is based on the concept that employs mathematics, theoretical chemistry, and computer science to predict the behavior of certain chemical frameworks at atomic levels^[42,43]. Electronic structure methods are the center of computational chemistry, which includes Hartree-Fock, post-Hartree-Fock, and density functional theory^[44,45]. Researchers could predict the molecular behavior through dealing with the Schrödinger equation. As a result, researchers will gain a comprehensive understanding of energy states, electronic interactions, and reaction mechanisms^[46,47]. Despite the challenges that computational chemistry encountered, the elevated accuracy of the forecasted information that these methods provide makes them essential and indispensable in practical methodologies^[48,49]. The initial application of this field in practice was in the 1930s, while more scope widening and greater advancements in computational power occurred since the 1960s^[40,50].

The applicability of the electronic structure methods in the larger molecular systems is computationally prohibitive. Therefore, classical mechanics, such as molecular mechanics, plays a crucial role in this field^[51,52]. These approaches employ previously characterized parameters like bond angles, lengths, and torsions to predict the molecular behavior of the system. Taking small molecules (e.g., H₂O, CO₂, and NO₂) as an instance, the vibrational behavior of these molecules could be well predicted using harmonic 3N-6 normal coordinates^[53,54]. Classical mechanics pick up the internal degrees of freedom for these systems, like angle bending and bond stretching. In addition, the potential for these vibrations to shift frequencies in response to structural framework alteration could also be described by classical mechanics^[55,56].

The accurate ability of modeling small molecules like CO₂ and NO₂ flashlight the applicability of classical mechanics to predict, with minimal computational effort, the vibrational spectra^[57,58]. In the case of condensed-phase systems, like molecular complexes in solvents, the prediction of the molecular behavior may be a challenging process with the computational models. For such cases, classical mechanics could provide affordable solutions, as it lacks the accuracy of the electronic structural methods in describing the electronic environments and the interactions of the systems^[59,60].

Many computational tools, like Monte Carlo and molecular dynamics simulations, combine both the electronic structure and the classical mechanical methods to predict the molecular behavior. While Monte Carlo simulation statistically investigates molecular conformations, molecular dynamics investigates the dynamic behavior by exploring the movement of the molecule over a specified time period. These tools are considered valuable investigative tools for exploring the energy landscapes of large biological molecules such as proteins or enzymes^[61-63].

The complexity of the molecular system in their condensed, solvent, or solid forms is the main persistent challenge that is encountered by these computational tools. Therefore, researchers attempt to create a hybrid approach that combines electronic structure and classical methods^[64,65]. For practical application, it is important to have the ability to transform between the highly accurate electronic structure method for local interactions and the effective classical methods for macromolecular behavior^[66,67]. Computational chemistry can reshape the field of drug discovery by grafting both of these methods into modern tools like machine learning and informatic-based techniques. Such grafting paved the way for researchers to link the theoretical and the experimental data, which enabled a comprehensive understanding of molecular systems and accelerated the steps of drug discovery^[68,69]. The main differences between the two computational approaches are summarized in **Table 1**.

Table 1. Comparison between the electronic structure and the classical mechanic methods.

Comparison points	Electronic structure methods	Classical mechanic methods
Principle	Depend on dealing with Schrödinger equation to predict the molecular behavior	Based on previously characterized parameters like bond angles and lengths to predict molecular system
Accuracy	High accuracy for energy states, electronic interactions, and reaction mechanisms	Predict molecular behavior although it lacks the accuracy for electronic interactions
Scale	Suitable for small molecules due to computational processing requirements	Suitable for larger systems like macromolecules and molecular complexes
applications	Studying electronic interactions in details	Feasible for modeling macromolecules and predicting the vibrational behavior
Challenges	Costly and limited applicability for macromolecules	Lacks the accuracy to describe the electronic interactions in complex systems
Examples	Hartree-Fock, post-Hartree-Fock, and density functional theory	Molecular dynamics, mechanics, and Monte Carlo

4. Computational approaches in drug discovery

4.1. Molecular modeling

Molecular modeling is the cornerstone of modern drug discovery efforts. It often involves the use of computer-based methods to simulate drug interactions with biological targets^[70,71]. These models aid researchers in comprehending the structural frameworks and behavior of different chemical and biological systems, providing essential insights for the development of viable medication candidates. Usually, the pipeline starts with making libraries of possible therapeutic molecules and biological targets. Next, the interactions between these molecules and targets are studied computationally^[72,73]. Two common molecular modeling techniques are ligand-based drug discovery and structure-based drug discovery.

4.1.1. Ligand-based drug discovery (LBDD)

This model depends on the understanding of molecules (ligands) that are already proven to interact with a target. LBDD emphasizes the structural characteristics of these active ligands, those with potential biological activities, to build novel candidates exhibiting analogous biological action. After analyzing well-known active ligands to determine the characteristics that lead to their binding, researchers assess related substances for their capacity to bind to the target^[74,75]. A prevalent method in LBDD is active-site modeling, which use three-dimensional representations of active drugs to emphasize common characteristics essential for binding to the target^[76,77]. Active-site models are established through investigating the essential attributes of active chemicals and are utilized to forecast and identify novel possible candidates^[78,79]. By directing the modification of chemicals from various chemical families, these models also make core-morphing easier, enabling researchers to investigate new chemical regions^[80,81]. LBDD is particularly advantageous when the target protein's structure is unidentified, as it depends on ligand knowledge instead of direct structural data. The technique has demonstrated efficacy in directing the creation of novel therapeutic candidates by utilizing the binding characteristics of established active compounds^[82,83].

4.1.2. Structure-based drug discovery (SBDD)

This model relies on the three-dimensional structure of the target macromolecule (receptor). Researchers could simulate the binding potential between the drug (ligand) molecule and the receptor by employing the computational techniques^[84,85]. SBDD starts by building the three-dimensional structure of the target receptor, often required to be soluble^[86,87]. Then, different groups of possible ligand molecules are docked with the target receptor using computers to show and measure the strength of their interaction^[88,89]. To design more efficient candidates, the molecular geometry and the electronic characteristics of the binding sites (pockets) are investigated and analyzed^[90-92].

In the field of drug discovery, SBDD occupies a wide area. One of the important examples was the identification of candidates that specifically targeted *Mycobacterium tuberculosis* proteins^[93,94]. Researchers employ the SBDD models to investigate specific structural fragments that could be utilized as initial scaffolds for novel antimycobacterial agents^[95-97]. The accelerated ability for screening and ranking the investigated chemical compounds, the enrichment of information about administration route, dosage, and possible side effects, and the streamlining of the process of drug developments are the main advantages that the SBDD modeling provides^[98,99]. Collectively, these models render molecular modeling a potent and adaptable instrument in drug development, allowing researchers to devise and refine therapeutic candidates with enhanced efficiency and accuracy. **Table 2** presents a concise summary of the distinctions between LBDD and SBDD.

Table 2. Comparison between LBDD and SBDD.

Comparison points	LBDD	SBDD
Dependency	On the knowledge of active ligand	On the three-dimensional structure of the target macromolecules
Approach	Concentrate on modeling and analyzing documented ligands to characterize the binding features	Simulate and analyze the interaction between ligands and targets through employing computational docking
Techniques employed	Active-site modeling to predict new ligands	Molecular docking and analysis of binding pockets to recognize and optimize the ligand-receptor interaction
Advantages	Suitable when receptor's structure is unknown employing ligand data instead.	Effective when receptor's structure is known, permits direct investigation of binding site.
Core investigation	Facilities core-morphing to investigate new candidates by modifying existing bioactive ligands	Concern with structural fragments of the receptor to optimize the interaction or to discover novel candidates
Efficiency	Relatively faster when exploring known ligand; used for identifying wide spectrum of potential drugs	Provide enriched data about the ligand-receptor interaction, which aid in effective candidates seeking and ranking.

4.2. Quantum mechanics

One powerful approach to simulation is to use techniques of quantum chemistry to describe both the electronic structure and the bonding that occurs in the drug-target system^[100,101]. Quantum chemistry, a subfield of computational chemistry, provides a powerful, accurate, yet computationally expensive means of modeling and designing molecules by solving Schrödinger's equation, which allows the quantum mechanical investigation of electronic states, molecular properties, and transitions^[102,103]. Given a particular molecular structure, the main goal of quantum chemistry is the accurate determination of the electronic wave function. From this electronic wave function, several important molecular properties can be obtained^[104,105].

Generally, there are two main classes of quantum chemical calculations: the ab initio method and the density functional theory^[106,107]. Both of these calculations enrich researchers with comprehensive information about the reaction reactivity by exploring energy diagrams, reaction pathways, and electrical features^[108,109]. In addition, quantum mechanics permit the computation of different electronic descriptors, like polarizability, electronegativity, and ionization potential, as well as chemical hardness and softness. With the aid of these descriptors, the relation between them and the training set's reactivity can be easily understood^[110,111].

4.3. Virtual screening techniques

Researchers utilized various tools and techniques to discover potential drug candidates. Molecular docking and pharmacophore modeling were among the most important tools^[112,113]. The easy reach of large libraries of ligands and the crystal structures of different receptors permits the emergence of effective docking programs. By using scoring functions, these programs can predict the strength of ligand-receptor interactions^[114,115]. Receptors are chosen based on their well-established roles in disease mechanisms, availability of high-resolution crystal structures from databases like the Protein Data Bank, and their suitability for computational modeling. Structural integrity, binding site accessibility, and experimental validation from literature also play crucial roles in this selection process^[116,117]. In addition, docking programs can deal with one or multiple targets at the same running time. Although this aids in identifying chemicals that had the potential to bind and interact with multiple targets, it also increases the risk of off-target effects. On the other hand, the pharmacophore-based modeling relies on the data provided by documented ligands and voids complex receptor realignment^[118,119]. The summarized steps for each tool are displayed in **Figure 2**.

4.3.1. Docking and scoring methods

This method simulates the potential interaction between ligands and their receptors to provide a general perspective about the ligand's biological activity. Based on their three-dimensional structures, docking evaluates the strength of interaction and creates forecasted models for potential candidates^[120,121]. In addition, this method employs the receptor's geometry to design models that provide precise ligand-receptor interaction, as displayed in **Figure 2**. By offering detailed insight into the binding mechanism, the docking tools potentially accelerate the process of drug discovery^[122,123].

4.3.2. Pharmacophore modeling

This model characterizes the geometric and the spatial properties that are essential for ligand-receptor interactions. Pharmacophore modeling aids in exploring similar compounds, evaluating chemical properties, and seeking new lead compounds^[124]. Homology^[125] or de novo modeling^[126] is utilized to predict the active-site properties of uncommon receptors, as displayed in **Figure 2**. The application of this model has mainly focused on finding new candidates for the most challenging pathogens, like Plasmodium^[127], Trypanosoma^[128], and Schistosoma mansoni^[129].




Figure 2. The summarized steps for docking and pharmacophore modeling methods.

4.4. Molecular dynamic simulations

Molecular dynamics (MD) simulations are among the essential tools in computational chemistry that enriched researchers with detailed information about the biomolecular systems at the atomic level^[130,131]. The strength of ligand-receptor interactions, molecular attraction/repulsion mechanisms, and receptor flexibility are the most important details provided by MD simulations^[132,133]. These simulations are also utilized for quantitative investigations, like evaluations of binding affinities for certain ligands^[134]. The increased

advancement in the MD tools facilitates the characterization of binding poses, reinforcing the concept of computational prediction in the field of drug discovery^[135,136].

4.4.1. Principle of MD simulations

The principle behind this approach depends on force fields and atomic models to assess the energy of the biomolecular system. The assessment starts with a computational calculation of the applied forces on each individual atom^[137,138]. After that, loopingly dealing with Newton's equations of motion to forecast the trajectories of atoms over a specified time period^[139,140]. The system's potential energy is described, by the force fields, as an integration of van der Waals, electrostatic, and bonded terms. The simulation's accuracy relies on the properties of the force field parameters^[141,142]. These parameters determine the stability of the ligands' conformations and characterize the potential energy of the biomolecular system. The higher the optimization of the force fields, the more robust the forecasting capabilities, as those systems that craft the density functional methods and the atomic point charges^[143,144].

4.4.2. Advancement and limitation in MD simulations

The classic MD simulation tools provide dynamic simulation for the biomolecular system in a nanosecond time scale. Now, the recent versions of offer simulation periods that extend to microsecond time scales^[145,146]. This extension in the time scale will offer a comprehensive understanding of the dynamic behavior of the investigated biomolecular system. However, this time extension requires more efficient computers that could process the data in a proper way^[147,148]. The efficiency and accuracy of these models are both limited by how well the underlying parameters are defined^[149,150]. The more rapid the development of computer efficiency and algorithms, the more optimized the force fields will be, which aids in higher predictive power of the MD simulations and makes them an indispensable tool in the field of drug discovery^[151,152].

4.4.3. MD simulation's tools and data analysis

The most popular in silico simulation tools and programs for MD simulations are AMBER, GROMACS, CHARMM, and NAMD. Because it offers the most optimal FF99SB force field, AMBER is a beneficial tool for simulating peptides, proteins, and nucleic acids^[153]. GROMACS is also appropriate for the simulation of nucleic acids^[154] and polypeptides^[155], as well as oligopeptides and lipid molecules^[156]. It is widely believed that CHARMM is an effective tool for simulating enzymes and other macromolecules^[157]. Lastly, NAMD's efficiency in parallel processing makes it an ideal tool for large-scale biomolecular research^[158]. Several visualization tools, including Chimera and PyMOL, are available to help make sense of the data and molecular trajectories that these programs offer^[159,160].

The data of MD simulations are provided as graphical charts that reveal the behavior of the biomolecule under investigation over the specified time period. The most valuable charts are the root mean square deviation (RMSD), root mean square fluctuation (RMSF), radius of gyration (Rg), and hydrogen bond (H-bond) charts^[161,162]. The atomic stability of the system is usually tracked by the RMSD chart, while the RMSF chart aids in the recognition of flexible regions in the biomolecules and the identification of active sites^[163,164]. System compactness-related data are provided by the Rg charts, and the H-bond analysis aids in the evaluation of the ligand-receptor complex interactions^[165,166]. **Figure 3** shows the MD simulation process, outlining the key steps involved in computational modeling of biomolecular systems. The process begins with input preparation, including the selection of the protein structure, ligand, solvent, and necessary charges. A suitable force field, such as ff14SB, CHARMM36, AMBER96, or FF99SB, is then assigned to define atomic interactions. The simulation itself is conducted by solving Newton's equations of motion through iterative time steps. Finally, the results are analyzed using key metrics such as RMSD for structural stability, RMSF for residue flexibility, Rg for molecular compactness, and hydrogen bonding interactions, providing crucial insights into biomolecular behavior. These metrics, together with the molecular visualization, provide

a deep insight into the dynamic features of the investigated biomolecular system, which makes the MD simulations a valuable tool in the field of drug discovery^[167–169].




Figure 3. The main components of MD simulation process.

4.5. Quantitative structure activity relationship (QSAR)

QSAR is a research area in chemistry where the total set of data on physical and chemical properties, reactivity, or biological activities of compounds is used to build models using statistically correlated molecular descriptors^[170,171]. The resulting model can be used for a variety of purposes, including predicting new biological activity or prioritizing a set of compounds for biological testing. As such, QSAR is an essential tool in the chemical, pharmaceutical, and materials industries, aiding various decision-making processes in chemical and materials design and application^[172,173]. QSAR techniques are based on the assumption that chemically and physically similar compounds have a similar biological activity. Therefore, either experimental or calculated molecular descriptors can be employed in a QSAR model based on the similarity of compounds^[174,175].


Statistically, QSAR uses the system data to build a predictive model for the system of interest. For any given set of experimental data, there is a unique set of parametrized equations that can fit it^[176,177]. These equations can be used to predict selectivity and to help deduce the mode of action, i.e., to provide the physicochemical rationalization of the results, which provide powerful guidance for medicinal chemists in the design and optimization of other specified structural requirements^[178,179]. QSAR models are commonly applied to estimate the toxicological profile of compounds during their chemical assessment for regulatory purposes, which is especially relevant to the pharmaceutical industry^[180,181].

4.5.1. Principle of QSAR

QSAR tries to model responses based on chemical structure. The assumption is that similar chemical compounds have similar biological activity. This model is a chemically informed isomorphism assumption^[182,183]. Mathematically, compounds are posited to dwell near points in a metric environment. The

transition from biological responses to chemical descriptors is accomplished predominantly through descriptor calculations. Therefore, a person who trusts the model also trusts the descriptors^[184,185].

The cornucopia of QSAR approaches has limited the enthusiasm for this area and its use in practice. They fall into the standard setting and the variant flotsam and jetsam setting; there's essentially no form of QSAR that hasn't been thought of^[186,187]. QSAR is the flipside of finding any dependence, i.e., many regressions, in the betting problem. QSAR searches for chemical insight in the fundamental pharmaceutical research setting^[188,189]. These approaches are by no means without their merits. Furthermore, they benefit from economies of scale. Regrettably, they are available in a large-scale format^[190]. The steps of QSAR modeling are outlined in **Figure 4**.



re 4. The steps of QSAR modeling.

Fig

4.5.2. Application of QSAR in drug discovery

The success story of computational chemistry is now very well recognized in drug discovery^[191,192]. It contributes to the drug discovery cycle mainly in two ways: accelerating the drug discovery process by taking sick molecules out from the broad screening list and validating the hit list before taking them through *in vitro* or *in vivo* assays, thus resulting in significant economic paybacks^[193,194]. The screenings of millions of virtual compounds not only identify leads from among the vast number of potential candidates but also allow a study of the structure–activity relationship and the interactions of small molecules with the active sites^[195,196]. Computational methods also play a vital part in predicting the pharmacokinetic and pharmacodynamic properties of existing molecules to see if they are lipophilic or polar enough, if they have hydrogen bond donor and acceptor functionalities, and their acceptability for further dosage determinations^[197–199].

4.6. Machine learning and artificial intelligence

Machine learning refers to methods that enable computers to "learn" from large datasets and evolve their representations of relationships in the data. Trained machine learning models can then make predictions for new data, providing the predictions are within the scope of the training data^[200,201]. Machine learning and artificial intelligence in general have shaken the technology world in recent years, with a broad range of

successful applications^[202,203]. As there is a large amount of interaction between the structural properties of the compounds and their bioactivity. These methods can also be very relevant for drug discovery^[204,205]. The methods in machine learning include visual searching of molecular databases, and applications of machine learning within these fields have seen significant growth over the last decade^[206]. Machine learning often finds its place in identifying patterns in chemistry, primarily helping to model bioactivities of small molecules using molecular descriptors, fingerprints, and/or systems like images^[207,208]. Machine learning applications are typified in the QSAR field and in the prediction of pharmacokinetic/toxicity properties of drug molecules^[209,210].

4.6.1. Types of machine learning algorithms

Machine learning algorithms make a qualitative transformation in the field of drug discovery. These algorithms expedite recognition of potential drug candidates through rapid analysis of complicated data records^[211]. In general, machine learning algorithms are classified into three groups: supervised, unsupervised, and reinforcement learning algorithms. For labeled data records, like molecular descriptors in relation to known bioactivities, it is prudent to apply supervised learning algorithms to predict features such as efficacy, toxicity, and binding affinities for new chemical compounds^[212]. Contrastly, for unlabeled data records, the application of the unsupervised algorithms is crucial, like grouping chemicals with identical features or diminishing the distraction of large screening records to permit easier analysis and visualization^[213]. The last algorithm is usually employed for two purposes: (a) positively tuning the molecular design process, as the chemicals are loopingly created, and (b) optimizing the molecular structure of the bioactive scaffolds to maximize the potency and synthetic feasibility^[214]. The detailed comparison between the three algorithms is listed in **Table 3**. Collectively, these algorithms decreased the obstacles that were encountered during the drug discovery process.

Table 3. Comparison between types of machine learning algorithms.

Comparison points	Supervised	Unsupervised	Reinforcement
Purpose	Predict specified features of chemicals	Recognize groups in chemicals data records	Aids in molecular designing and optimize molecular scaffolds to maximize efficacy
Training data	Labeled data records	Unlabeled data records	Performance-oriented rewards
Application	Predict pharmacokinetic / toxicity features	Grouping identical chemicals and aid in easier analysis	Discovering novel candidates with optimal features
Advantages	Accuracy of prediction	Recognize novel correlations in data records	Create novel candidates
Limitation	Necessitates costly labeled data records	Lack outputs interpretations	Necessitates efficient computational power and well-recognized rewards criteria

4.6.2. Applications in drug discovery

The real revolution in the drug discovery field was initiated by the advancement in machine learning and the artificial intelligence programs. These advancements allow for more precise and proficient methods to identify the lead compounds^[215]. The involvement of machine learning and artificial intelligence programs in virtual screening has a significant impact on accelerating drug discovery^[216]. This results in a reduction in the number of in vitro and in vivo experiments required to identify and assess compounds with promising drug eligibility features as potential lead compounds^[217,218]. In addition to the advancement in the virtual screening, cheminformatics becomes crucial in the field of drug discovery. Cheminformatics boosts the process of drug discovery by its incredible ability to deal with and analyze huge data records^[219]. Furthermore, cheminformatics employed reaction modeling techniques, molecular structure representations, and chemical feature calculations to aid in chemical selection and optimization^[220]. Hybridized approaches of

machine learning, artificial intelligence, and cheminformatics permit the proficient recognition of the bioactive chemicals and forecasting molecular features. Such hybridized tools steeply accelerate the drug discovery process^[221,222].

5. Computational chemistry in medicinal practice

Currently, a sizable portion of the drug discovery sector is devoted to computational chemistry, which attracts researchers with data that allows them to forecast molecular behavior and improve drug prospects. In medical practice, computational chemistry become indispensable tool that has various application in different medical aspects^[223]. The main contributions of computational chemistry could be outlined in its success in addressing global health challenges^[224]. The most important applications are outlined in **Figure 5**.

5.1. Drug repurposing

The worldwide outbreak stemming from coronavirus brought attention to the crucial role of computational chemistry tools in boosting the process of drug discovery^[225,226]. Drug repurposing, which deals with recognizing novel uses for established drugs in the markets, evolved as a quick and efficient method for developing viral-fighting agents^[227]. Artificial intelligence played a crucial role in accelerating this process by integrating predictive models with computational chemistry techniques to identify potential drug candidates rapidly^[228]. Tools of computational chemistry, like molecular docking and MD simulations, have been utilized to discover drug candidates that specifically targeted the coronavirus enzymes^[229]. These approaches were further enhanced by Artificial intelligence-driven algorithms that improved the accuracy of molecular interactions and reduced the time required for screening potential therapeutics^[230]. Virtual screening tools make it easy to quickly screen large chemical libraries^[231]. These libraries include phytochemicals like coumarins^[232,233], flavonoids^[234], and alkaloids^[235], which are known to fight viruses. Hybrid approaches that combine AI, machine learning, and computational chemistry have significantly improved drug discovery by refining molecular selection processes, optimizing docking scores, and predicting pharmacokinetic properties with higher precision^[230]. Computational chemistry laid the groundwork for later validations *in vitro* and *vivo* by finding molecules that have drug-like features. These molecules will eventually help the global fight against this outbreak^[236].

5.2. Personalized medicaments

The steep development in the genetic studies has established the foundations for personalized medicaments^[237]. This concept means that a therapeutic agent would be tailored according to the distinct genetic map of each individual patient^[238]. In this field, computational chemistry played a significant role by designing and discovering novel medicaments that selectively match with the genetic polymorphism that is responsible for underlying pathologies^[239]. This selectivity diminished the possibility of unwanted effects and got rid of the time and cost wasted on experimental trials^[240]. By crafting genetic data records with the computational tools, there is a significant improvement in terms of dose regimens adjustment, efficacy optimization, and enhancement of patient compliance^[232]. In addition to the progress of the therapeutic outcomes, personalized medicaments also decrease the medical expenditure by reducing the utility of ineffective medicaments^[241,242].

5.3. Miscellaneous applications

The tools and techniques of computational chemistry were employed in a wide spectrum of applications in medicinal practice. It plays a crucial role in the investigation of rare and uncommon illnesses by identifying potential medicines to treat conditions that lack funding or researchers' attention^[243]. In cancer therapy, computational chemistry facilitates the design of selectively targeted drugs by simulating molecular interactions and behaviors between the drug and tumor biomarkers^[244,245]. Moreover, these technologies

substantially aid in addressing the global challenge of antimicrobial-resistant microorganisms by finding possible targets for these pathogens^[246]. Furthermore, computational chemistry has a clear fingerprint in forecasting the pharmacokinetic and toxicity profiles, improvement of medicament formulations, and the solubility and stability of the candidates. Computational chemistry has numerous applications, and these examples show how it may solve difficult problems and spur innovation in the pharmacy sector^[247].




Figure 5. Applications of computational chemistry in medicinal practice.

6. Limitation and challenges in computational chemistry

While computational drug discovery has made steep progress, some issues still exist that compromise the dependability and usability of these approaches. The computational methods depend on approximations that might not completely replicate biological complexity like protein flexibility and solvation impacts^[248]. To address these constraints, there are recent developments like ensemble docking, machine learning-driven scoring systems, and improved sampling techniques^[249]. Considerable-scale virtual screening and high-resolution simulations also need considerable computational resources, which presents difficulties for research groups without access to high-performance computing. Potential fixes have been explored, including the integration of cloud computing, GPU acceleration, and prediction models driven by artificial intelligence^[250]. Furthermore, computational forecasts call for experimental validation, which can be time-consuming and expensive; some expected drugs fail to show promised action in vitro and in vivo. Hybrid methods, those combining computer forecasts with automated high-throughput screening, are in development and expected to solve these concerns^[251]. Challenges in biased datasets, overfitting, and lack of interpretability abound in artificial intelligence-driven drug discovery as well. Efforts in explainable artificial intelligence, data augmentation, and federated learning are strengthening these approaches' openness and resilience. Still major issues are ethical and regulatory ones like data privacy, repeatability, and artificial intelligence-generated molecular evaluation^[252]. These days, regulatory authorities are looking at systems stressing openness, repeatability, and ethical norm compliance. Although these difficulties still exist, constant developments in computational techniques, artificial intelligence, and integrated approaches are gradually conquering these constraints. Refining prediction accuracy, enhancing computing efficiency, and

boosting experimental validation procedures will help to accelerate the identification of new drug candidates, hence defining the future of computational drug development^[253].

7. Conclusion

Computational chemistry now occupies a substantial area in the field of drug discovery that recruits researchers with data that enable them to predict molecular behavior and refine drug candidates. Consequently, there is a significant reduction in time and cost that is associated with conducting traditional experimental methods. By employing the tools of computational chemistry—molecular docking, pharmacophore modeling, MD simulations, QSAR, and virtual screening—computational chemistry becomes able to recognize drug candidates with promising bioactivities. Our review highlights how these methods contribute to target identification, lead optimization, and pharmacokinetic profiling, ultimately accelerating drug discovery process. It provides significant data that enables a comprehensive understanding of the pathogenesis of the disease, boosting the process of drug design, and facilitates the converting of the theoretical data into real candidates, those ready for experimental validation. The horizon of the drug discovery process will mainly depend on the updated computational tools and techniques. These techniques are expected to be able to characterize compounds that are efficient, target-selective, and absorbable, thereby enhancing the drug discovery process. Moreover, we have emphasized the growing role of artificial intelligence and machine learning in computational drug discovery, demonstrating their ability to refine molecular predictions, automate data analysis, and streamline drug screening. Hybrid approaches, which combine computational and pharmacological methodologies with machine learning and artificial intelligence, significantly enhance drug discovery efforts. This kind of hybridization is expected to accelerate the drug discovery pipeline, improve the success outcomes, and reduce the cost of experimental procedures. The integration of these tools into current drug discovery workflows is expected to bridge the gap between in silico predictions and experimental validation, ultimately leading to more effective and rapidly developed therapeutic solutions. Thus, the computational chemistry would be the primary motivator of the pharmaceutical sciences advancement in the foreseeable future.

Conflict of interest

The authors declare no conflict of interest.

References

1. DiMasi JA. Research and Development Costs of New Drugs. *JAMA*. 2020;324(5):517.
2. Singh N, Vayer P, Tanwar S, Poyet JL, Tsaïoun K, Villoutreix BO. Drug discovery and development: introduction to the general public and patient groups. *Frontiers in Drug Discovery*. 2023;3.
3. Agrahari B, Layek S, Ganguly R, Dege N, Pathak DD. Synthesis, characterization and single crystal X-ray studies of pincer type Ni(II)-Schiff base complexes: Application in synthesis of 2-substituted benzimidazoles. *Journal of Organometallic Chemistry*. 2019;890:13–20.
4. Zeki NM, Mustafa YF. Novel heterocyclic coumarin annulates: synthesis and figuring their roles in biomedicine, bench-to-bedside investigation. *Chemical Papers*. 2024;78: 4935–4951.
5. Emens LA, Romero PJ, Anderson AC, Bruno TC, Capitini CM, Collyar D, Gulley JL, Hwu P, Posey AD, Silk AW, Wargo JA. Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision. *Journal for ImmunoTherapy of Cancer*. 2024;12(6):e009063.
6. Deore AB, Dhumane JR, Wagh R, Sonawane R. The Stages of Drug Discovery and Development Process. *Asian Journal of Pharmaceutical Research and Development*. 2019;7(6):62–7.
7. Mustafa YF, Abdulaziz NT. Biological potentials of hymecromone-based derivatives: A systematic review. *Systematic Reviews in Pharmacy*. 2020;11(11):438–52.
8. Bashir MK, Mustafa YF, Oglah MK. Synthesis and antitumor activity of new multifunctional coumarins. *Periodico Tche Quimica*. 2020;17(36):871–83.
9. Mustafa YF. Triple coumarin-based 5-fluorouracil prodrugs, their synthesis, characterization, and release kinetics. *Journal of Molecular Structure*. 2024;1301:137415.

10. Kiriiri GK, Njogu PM, Mwangi AN. Exploring different approaches to improve the success of drug discovery and development projects: a review. *Future Journal of Pharmaceutical Sciences*. 2020;6(1):27.
11. Núñez S, Venhorst J, Kruse CG. Target–drug interactions: first principles and their application to drug discovery. *Drug Discovery Today*. 2012;17(1–2):10–22.
12. Bajorath J. Pushing the Boundaries of Computational Approaches: Special Focus Issue on Computational Chemistry and Computer-Aided Drug Discovery. *Future Medicinal Chemistry*. 2015;7(18):2415–7.
13. Raza MA, Farwa U, Danish M, Ozturk S, Aagar AA, Dege N, Rehman SU, Al-Sehemi AG. Computational modeling of imines based anti-oxidant and anti-esterases compounds: Synthesis, single crystal and In-vitro assessment. *Computational Biology and Chemistry*. 2023;104:107880.
14. Mustafa YF, Mohammed ET, Khalil RR. Antioxidant and antitumor activities of methanolic extracts obtained from Red Delicious and Granny Smith apples' seeds. *Systematic Reviews in Pharmacy*. 2020;11(4):570–6.
15. Bajorath J, Jiang H, Shoichet BK, Walters WP. Computational Methods for Medicinal Chemistry. *Journal of Medicinal Chemistry*. 2015;58(3):1019–1019.
16. Tahir MN, Ashfaq M, Feizi-Dehnyebi M, Munawar KS, Atalay Ş, Dege N, Guliyeva N, Sultan A. Crystal structure, Hirshfeld surface analysis, computational study and molecular docking simulation of 4-aminoantipyrine derivative. *Journal of Molecular Structure*. 2025;1320:139747.
17. Mahamat H. The impact of computational chemistry on modern drug discovery. *International Journal of Advanced Chemistry Research*. 2022;4(2):398–400.
18. Singh DB, Pathak RK, Rai D. from traditional herbal medicine to rational drug discovery: strategies, challenges, and future perspectives. *Revista Brasileira de Farmacognosia*. 2022;32(2):147–59.
19. Oselusi SO, Dube P, Odugbemi AI, Akinyede KA, Ilori TL, Egieyeh E, Sibuyi NR, Meyer M, Madiehe AM, Wyckoff GJ, Egieyeh SA. The role and potential of computer-aided drug discovery strategies in the discovery of novel antimicrobials. *Computers in Biology and Medicine*. 2024;169:107927.
20. Hughes J, Rees S, Kalindjian S, Philpott K. Principles of early drug discovery. *British Journal of Pharmacology*. 2011;162(6):1239–49.
21. Khalil RR, Mohammed ET, Mustafa YF. Evaluation of in vitro antioxidant and antidiabetic properties of *Cydonia Oblonga* seeds' extracts. *Journal of Medicinal and Chemical Sciences*. 2022;5(6):1048–58.
22. Das B, Baidya ATK, Mathew AT, Yadav AK, Kumar R. Structural modification aimed for improving solubility of lead compounds in early phase drug discovery. *Bioorganic & Medicinal Chemistry*. 2022;56:116614.
23. Mustafa YF, Faisal AF, Alshaher MM, Hassan DA. Food-derived micronutrients as alleviators of age-related dysfunction: a dive into their effects and cellular mechanisms. *Indian Journal of Clinical Biochemistry*. 2025; <https://doi.org/10.1007/s12291-024-01297-7>
24. Hefti FF. Requirements for a lead compound to become a clinical candidate. *BMC Neuroscience*. 2008;9(S3):S7.
25. Mustafa YF, Hassan DA. Dioxolocoumarins: Bridging chemistry and pharmacology with multifunctional therapeutics. *Applied Chemical Engineering*. 2024;7(4):5592.
26. Webborn PJ. The Role of Pharmacokinetic Studies in Drug Discovery: Where are We Now, How Did We Get Here and Where are We Going? *Future Medicinal Chemistry*. 2014;6(11):1233–5.
27. Sanap SN, Bisen AC, Kedar A, Agrawal S, Bhatta RS. Recent Update on Pharmacokinetics and Drug Metabolism in CNS-based Drug Discovery. *Current Pharmaceutical Design*. 2023;29(20):1602–16.
28. Mustafa YF, Oglah MK, Bashir MK. Conjugation of sinapic acid analogues with 5- Fluorouracil: Synthesis, preliminary cytotoxicity, and release study. *Systematic Reviews in Pharmacy*. 2020;11(3):482–9.
29. Aldewachi H, Mustafa YF, Najm R, Ammar F. Adulteration of Slimming Products and its Detection Methods. *Systematic Reviews in Pharmacy*. 2020;11(3):289–96.
30. Alshaher MM, Mustafa YF. Synthesis of triclosan-derived coumarins as potent, biocompatible, broad-spectrum antimicrobial agents. *Applied Chemical Engineering*. 2024;7(4):5579.
31. Yu CX, Tham CL. Drug discovery and development: A historical overview, current challenges and perspectives. *Life Sciences, Medicine and Biomedicine*. 2024;8(1).
32. Berdigaliyev N, Aljofan M. An Overview of Drug Discovery and Development. *Future Medicinal Chemistry*. 2020;12(10):939–47.
33. Hachem K, Jasim SA, Al-Gazally ME, Riadi Y, Yasin G, Turki Jalil A, Abdulkadhm MM, Saleh MM, Fenjan MN, Mustafa YF, Dehno Khalaji A. Adsorption of Pb(II) and Cd(II) by magnetic chitosan-salicylaldehyde Schiff base: Synthesis, characterization, thermal study and antibacterial activity. *Journal of the Chinese Chemical Society*. 2022;69(3):512–21.
34. Faisal AF, Mustafa YF. The role of coumarin scaffold in the chemical engineering of bioactive molecules: A narrative review. *Applied Chemical Engineering*. 2025;8(1):5595.
35. Cai JH, Zhu XZ, Guo PY, Rose P, Liu XT, Liu X, Zhu YZ. Recent updates in click and computational chemistry for drug discovery and development. *Frontiers in Chemistry*. 2023;11.
36. Mustafa YF, Khalil RR, Mohammed ET. Antimicrobial activity of aqueous extracts acquired from the seeds of two apples' cultivars. *Systematic Reviews in Pharmacy*. 2020;11(2):382–7.
37. Kalai F El, Çınar EB, Lai CH, Daoui S, Chelfi T, Allali M, Dege N, Karrouchi K, Benchat N. Synthesis, spectroscopy, crystal structure, TGA/DTA study, DFT and molecular docking investigations of (E)-4-(4-methylbenzyl)-6-styrylpyridazin-3(2H)-one. *Journal of Molecular Structure*. 2021;1228:129435.

38. Cavasotto CN, Aucar MG, Adler NS. Computational chemistry in drug lead discovery and design. *International Journal of Quantum Chemistry*. 2019;119(2).
39. Hussein HK, Aubead M, Kzar HH, Karim YS, Amin AH, Gazally ME Al, Ahmed TI, Jawad MA, Hammid AT. Association of cord blood asprosin concentration with atherogenic lipid profile and anthropometric indices. *Diabetology & Metabolic Syndrome*. 2022;14:74.
40. Baldi A. Computational approaches for drug design and discovery: An overview. *Systematic Reviews in Pharmacy*. 2010;1(1):99.
41. Mustafa YF. Harmful Free Radicals in Aging: A Narrative Review of Their Detrimental Effects on Health. *Indian Journal of Clinical Biochemistry*. 2024; 154–167
42. Roomi AB, Widjaja G, Savitri D, Jalil AT, Mustafa YF, Thangavelu L, Kazhibayeva G, Suksatan W, Chupradit S, Aravindhana S. SnO₂:Au/Carbon Quantum Dots Nanocomposites: Synthesis, Characterization, and Antibacterial Activity. *Journal of Nanostructures*. 2021;11(3):514–23.
43. Jebir RM, Mustafa YF. Watermelon Allsweet: A promising natural source of bioactive products. *Journal of Medicinal and Chemical Sciences*. 2022;5(5):652–66.
44. Brahim M, Belmiloud Y, Kheffache D. Hartree-Fock, Post Hartree-Fock and density functional theory studies on structure and conformational stability of N-Methylen-Formamide (NMF) and substituted compounds of NMF. *Journal of Molecular Structure: THEOCHEM*. 2006;759(1–3):1–10.
45. Jasim SF, Mustafa YF. A Review of Classical and Advanced Methodologies for Benzocoumarin Synthesis. *Journal of Medicinal and Chemical Sciences*. 2022;5(5):676–94.
46. Manzhos S, Ihara M, Carrington T. Using Collocation to Solve the Schrödinger Equation. *Journal of Chemical Theory and Computation*. 2023;19(6):1641–56.
47. Huldani H, Rashid AI, Turaev KN, Oplencia MJC, Abdelbasset WK, Bokov DO, Mustafa YF, Al-Gazally ME, Hammid AT, Kadhim MM, Ahmadi SH. Concanavalin A as a promising lectin-based anti-cancer agent: the molecular mechanisms and therapeutic potential. *Cell Communication and Signaling*. 2022;20:167.
48. Mustafa YF, Abdulaziza NT, Jasima MH. 4-Methylumbelliferone and its derived compounds: A brief review of their cytotoxicity. *Egyptian Journal of Chemistry*. 2021;64(4):1807–16.
49. Abdulaziz NT, Mustafa YF. Antibacterial and Antitumor Potentials of Some Novel Coumarins. *International Journal of Drug Delivery Technology*. 2022;12(1):239–47.
50. Ismael RN, Mustafa YF, Al-Qazaz HK. Citrullus lanatus, a Potential Source of Medicinal Products: A Review. *Journal of Medicinal and Chemical Sciences*. 2022;5(4):607–18.
51. Raya I, Chupradit S, Kadhim MM, Mahmoud MZ, Jalil AT, Surendar A, Ghafel ST, Mustafa YF, Bochar AN. Role of Compositional Changes on Thermal, Magnetic and Mechanical Properties of Fe-P-C-Based Amorphous Alloys. *Chinese Physics B*. 2022;31(1):016401.
52. Jasim SF, Mustafa YF. New fused-coumarin composites: synthesis, anticancer and antioxidant potentials evaluation. *Eurasian Chemical Communications*. 2022;4(7):607–19.
53. Nejres AM, Ali HK, Behnam SP, Mustafa YF. Potential effect of ammonium chloride on the optical physical properties of polyvinyl alcohol. *Systematic Reviews in Pharmacy*. 2020;11(6):726–32.
54. Ismael RN, Mustafa YF, Al-Qazaz HK. Cancer-curative potential of novel coumarins from watermelon princess: A scenario of their isolation and activity. *Eurasian Chemical Communications*. 2022;4(7):657–72.
55. Tuccinardi T. What is the current value of MM/PBSA and MM/GBSA methods in drug discovery? *Expert Opinion on Drug Discovery*. 2021;16(11):1233–7.
56. Kar RK. Benefits of hybrid QM/MM over traditional classical mechanics in pharmaceutical systems. *Drug Discovery Today*. 2023;28(1):103374.
57. Mustafa YF, Mohammed N.A.-A. A promising oral 5-fluorouracil prodrug for lung tumor: Synthesis, characterization and release. *Biochemical and Cellular Archives*. 2021;21(Supp 1):1991–9.
58. Kasim SM, Abdulaziz NT, Jasim MH, Mustafa YF. Resveratrol in cancer chemotherapy : Is it a preventer , protector , or fighter ? *Eurasian Chemical Communications*. 2023;5(7):576–87.
59. Barbault F, Maurel F. Simulation with quantum mechanics/molecular mechanics for drug discovery. *Expert Opinion on Drug Discovery*. 2015;10(10):1047–57.
60. Balasubramanian K. Mathematical and Computational Techniques for Drug Discovery: Promises and Developments. *Current Topics in Medicinal Chemistry*. 2019;18(32):2774–99.
61. Velikova T, Mileva N, Naseva E. Method “Monte Carlo” in healthcare. *World Journal of Methodology*. 2024;14(3).
62. Adelusi TI, Oyedele AQK, Boyenle ID, Ogunlana AT, Adeyemi RO, Ukachi CD, Idris MO, Olaoba OT, Adedotun IO, Kolawole OE, Xiaoxing Y, Abdul-Hammed M. Molecular modeling in drug discovery. *Informatics in Medicine Unlocked*. 2022;29:100880.
63. Salo-Ahen OMH, Alanko I, Bhadane R, Bonvin AMJJ, Honorato RV, Hossain S, Juffer AH, Kabedev A, Lahtela-Kakkonen M, Larsen AS, Lescrinier E, Marimuthu P, Mirza MU, Mustafa G, Nunes-Alves A, Pantsar T, Saadabadi A, Singaravelu K, et al. Molecular Dynamics Simulations in Drug Discovery and Pharmaceutical Development. *Processes*. 2020;9(1):71.

64. Huang X, Niu L, Chen J, Li L, Hayat K, Liu W. Quantum and classical computational synergy for emerging contaminants management: Advanced insights into cytochrome P450 metabolic mechanisms. *Critical Reviews in Environmental Science and Technology*. 2024;54(24):1827–51.
65. Kasim SM, Al-Dabbagh BM, Mustafa YF. A review on the biological potentials of carbazole and its derived products. *Eurasian Chemical Communications*. 2022;4(6):495–512.
66. Bashir MK, Mustafa YF, Oglah MK. Antitumor, antioxidant, and antibacterial activities of glycosyl-conjugated compounds: A review. *Systematic Reviews in Pharmacy*. 2020;11(4):175–87.
67. Waheed SA, Mustafa YF. The in vitro effects of new albocarbon-based coumarins on blood glucose-controlling enzymes. *Journal of Medicinal and Chemical Sciences*. 2022;5(6):954–67.
68. Avramouli M, Savvas IK, Vasilaki A, Garani G. Unlocking the Potential of Quantum Machine Learning to Advance Drug Discovery. *Electronics*. 2023;12(11):2402.
69. Kulkarni PU, Shah H, Vyas VK. Hybrid Quantum Mechanics/Molecular Mechanics (QM/MM) Simulation: A Tool for Structure-Based Drug Design and Discovery. *Mini-Reviews in Medicinal Chemistry*. 2022;22(8):1096–107.
70. Aminpour M, Montemagno C, Tuszynski JA. An Overview of Molecular Modeling for Drug Discovery with Specific Illustrative Examples of Applications. *Molecules*. 2019;24(9):1693.
71. Abdulaziz NT, Mustafa YF. The Effect of Heat Variable on the Chemical Composition and Bioactivities of a *Citrullus lanatus* Seed Aqueous Extracts. *Journal of Medicinal and Chemical Sciences*. 2022;5(7):1166–76.
72. Mehta P, Miszta P, Filipek S. Molecular Modeling of Histamine Receptors—Recent Advances in Drug Discovery. *Molecules*. 2021;26(6):1778.
73. Abdulaziz NT, Al-bazzaz FY, Mustafa YF. Natural products for attenuating Alzheimer’s disease: A narrative review. *Eurasian Chemical Communications*. 2023;5(4):358–70.
74. Ye J, Yang X, Ma C. Ligand-Based Drug Design of Novel Antimicrobials against *Staphylococcus aureus* by Targeting Bacterial Transcription. *International Journal of Molecular Sciences*. 2022;24(1):339.
75. Ahmed BA, Mustafa YF, Ibrahim BY. Isolation and characterization of furanocoumarins from Golden Delicious apple seeds. *J Med Chem Sci*. 2022;5:537–45.
76. Zadeh FA, Bokov DO, Salahdin OD, Abdelbasset WK, Jawad MA, Kadhim MM, Qasim MT, Kzar HH, Al-Gazally ME, Mustafa YF, Khatami M. Cytotoxicity evaluation of environmentally friendly synthesis Copper/Zinc bimetallic nanoparticles on MCF-7 cancer cells. *Rendiconti Lincei*. 2022;33(2):441–7.
77. Al-Shakarchi W, Abdulaziz NT, Mustafa YF. A review of the chemical, pharmacokinetic, and pharmacological aspects of quercetin. *Eurasian Chemical Communications*. 2022;4(7):645–56.
78. Mustafa YF. Chemotherapeutic applications of folate prodrugs: A review. *NeuroQuantology*. 2021;19(8):99–112.
79. Mustafa YF, Bashir MK, Oglah MK. Influence of albocarbon-cyclic hybridization on biomedical activities: A review. *Journal of Medicinal and Chemical Sciences*. 2022;5(4):518–35.
80. Muhammed MT, Aki-Yalcin E. Pharmacophore Modeling in Drug Discovery: Methodology and Current Status. *Journal of the Turkish Chemical Society Section A: Chemistry*. 2021;8(3):749–62.
81. Javid A, Fatima A, Hamad M, Ahmed M. From roots to codes: Applications of computer-aided drug discovery from medicinal plants. *South African Journal of Botany*. 2024;173:159–74.
82. Nascimento IJ dos S, de Aquino TM, da Silva-Júnior EF. The New Era of Drug Discovery: The Power of Computer-aided Drug Design (CADD). *Letters in Drug Design & Discovery*. 2022;19(11):951–5.
83. Jebir RM, Mustafa YF. Kidney stones : natural remedies and lifestyle modifications to alleviate their burden. *International Urology and Nephrology*. 2024;56(3):1025–33
84. Shamsi A, Khan MS, Yadav DK, Shahwan M, Furkan M, Khan RH. Structure-based drug-development study against fibroblast growth factor receptor 2: molecular docking and Molecular dynamics simulation approaches. *Scientific Reports*. 2024;14(1):19439.
85. Zeki NM, Mustafa YF. Coumarin hybrids for targeted therapies: A promising approach for potential drug candidates. *Phytochemistry Letters*. 2024;60:117–33.
86. Jasim SF, Mustafa YF. Synthesis, ADME Study, and Antimicrobial Evaluation of Novel Naphthalene-Based Derivatives. *Journal of Medicinal and Chemical Sciences*. 2022;5(5):793–807.
87. Hammoodi SH, Ismael SS, Mustafa YF. Mutual prodrugs for colon targeting: A review. *Eurasian Chemical Communications*. 2022;4(12):1251–65.
88. Mohammed ET, Khalil RR, Mustafa YF. Phytochemical Analysis and Antimicrobial Evaluation of Quince Seeds’ Extracts. *Journal of Medicinal and Chemical Sciences*. 2022;5(6):968–79.
89. Zeki NM, Mustafa YF. Natural linear coumarin-heterocyclic conjugates: A review of their roles in phytotherapy. *Fitoterapia*. 2024;175:105929.
90. Wang DD, Wu W, Wang R. Structure-based, deep-learning models for protein-ligand binding affinity prediction. *Journal of Cheminformatics*. 2024;16(1):2.
91. Younes HA, Mustafa YF. Sweet Bell Pepper: A Focus on Its Nutritional Qualities and Illness-Alleviated Properties. *Indian Journal of Clinical Biochemistry*. 2024;39:459–69.
92. Arooj M, Sakkiah S, Cao GP, Kim S, Arulapperumal V, Lee KW. Finding off-targets, biological pathways, and target diseases for chymase inhibitors via structure-based systems biology approach. *Proteins: Structure, Function, and Bioinformatics*. 2015;83(7):1209–24.

93. Bruch EM, Petrella S, Bellinzoni M. Structure-Based Drug Design for Tuberculosis: Challenges Still Ahead. *Applied Sciences*. 2020;10(12):4248.
94. Mustafa YF. Effects of heat variables on the starch content of cooked white rice: Searching for diabetes-friendly food. *Bioactive Carbohydrates and Dietary Fibre*. 2024;31:100395.
95. Azman AA, Leow ATC, Noor NDM, Noor SAM, Latip W, Ali MSM. Worldwide trend discovery of structural and functional relationship of metallo- β -lactamase for structure-based drug design: A bibliometric evaluation and patent analysis. *International Journal of Biological Macromolecules*. 2024;256:128230.
96. Jibroo RN, Mustafa YF, Al-Shakarchi W. Synthesis and evaluation of linearly fused thiazolocoumarins as prospects with broad-spectrum bioactivity. *Results in Chemistry*. 2024;7:101494.
97. Arumugam N, Almansour AI, Kumar RS, Siva Krishna V, Sriram D, Dege N. Stereoselective synthesis and discovery of novel spirooxindolopyrrolidine engrafted indandione heterocyclic hybrids as antimycobacterial agents. *Bioorganic Chemistry*. 2021;110:104798.
98. Aarthy M, Panwar U, Selvaraj C, Singh SK. Advantages of Structure-Based Drug Design Approaches in Neurological Disorders. *Current Neuropharmacology*. 2017;15(8).
99. Mustafa YF. 4-Chloroskimmetine-based derivatives as potential anticancer and antibacterial prospects: Their synthesis and in vitro inspections. *Results in Chemistry*. 2024;7:101511.
100. Mustafa YF, Zain Al-Abdeen SH, Khalil RR, Mohammed ET. Novel functionalized phenyl acetate derivatives of benzo [e]-bispyrone fused hybrids: Synthesis and biological activities. *Results in Chemistry*. 2023;5:100942.
101. Mustafa YF. Nutraceutical-based telomerase inhibitors: Renewed hope for cancer therapy. *Phytomedicine Plus*. 2024;4(2):100537.
102. Jasim SF, Mustafa YF. Synthesis and antidiabetic assessment of new coumarin-disubstituted benzene conjugates : An in silico-in vitro study. *Journal of Medicinal and Chemical Sciences*. 2022;5(6):887–99.
103. Younes AH, Mustafa YF. Novel coumarins from green sweet bell pepper seeds: Their isolation, characterization, oxidative stress-mitigating, anticancer, anti-inflammatory, and antidiabetic properties. *Journal of Molecular Structure*. 2024;1312:138629.
104. Pris FI. The real meaning of quantum mechanics. *Educational Philosophy and Theory*. 2024;56(14):1361–5.
105. Jiang T, Guo Z, Zhang D, Vasil'ev VI. A fast algorithm for the Schrödinger equation in quaternionic quantum mechanics. *Applied Mathematics Letters*. 2024;150:108975.
106. Waheed SA, Mustafa YF. Benzocoumarin backbone is a multifunctional and affordable scaffold with a vast scope of biological activities. *Journal of Medicinal and Chemical Sciences*. 2022;5(5):703–21.
107. Younes AH, Mustafa YF. Plant-Derived Coumarins: A Narrative Review Of Their Structural And Biomedical Diversity. *Chemistry & Biodiversity*. 2024;21(6):e202400344.
108. Mustafa YF, Ismael RN, Jebir RM. Natural coumarins from two cultivars of watermelon seeds as biosafe anticancer agents, an algorithm for their isolation and evaluation. *Journal of Molecular Structure*. 2024;1295(P1):136644.
109. Younes AH, Mustafa YF. Unveiling the Biomedical Applications of Novel Coumarins Isolated From Capsicum Annuum L. Seeds by a Multivariate Extraction Technique. *Chemistry and Biodiversity*. 2024;21(6):e202400581.
110. Aysa NH, Aziz SW, Al-Assaly R. Novel in silico nano-drug design and delivery systems employing the density functional theory: a review. *Review of Clinical Pharmacology and Pharmacokinetics - International Edition*. 2024;38(Sup2):193–6.
111. Wang T, He X, Li M, Li Y, Bi R, Wang Y, Cheng C, Shen X, Meng J, Zhang H, Liu H, Wang Z, Li S, Shao B, Liu TY. Ab initio characterization of protein molecular dynamics with AI2BMD. *Nature*. 2024;635(8040):1019–27.
112. Mustafa YF. Coumarins from carcinogenic phenol: synthesis, characterization, in silico, biosafety, anticancer, antioxidant, and anti-inflammatory assessments. *Chemical Papers*. 2024;78(1):493–504.
113. Zeki NM, Mustafa YF. Coumarin hybrids: a sighting of their roles in drug targeting. *Chemical Papers*. 2024;78(10):5753–72.
114. Mustafa YF. Synthesis , in silico analysis , and biomedical effects of coumarins derived from resveratrol. *Phytomedicine Plus*. 2024;3(4):100501.
115. Mustafa YF, Bashir MK, Oglah MK. Synthesis, antioxidant and antitumor activities of new coumarins grafted to 5-fluorouracil. *Caspian Journal of Environmental Sciences*. 2022;20(2):359–65.
116. Wang N, Wang L, Xie XQ. ProSelection: A Novel Algorithm to Select Proper Protein Structure Subsets for in Silico Target Identification and Drug Discovery Research. *Journal of Chemical Information and Modeling*. 2017;57(11):2686–98.
117. Bulut A, Yesilel OZ, Dege N, Icbudak H, Olmez H, Buyukgungor O. Dinicotinamidium squarate. *Acta Crystallographica Section C Crystal Structure Communications*. 2003;59(12):o727–9.
118. Muhammed MT, Aki-Yalcin E. Molecular Docking: Principles, Advances, and Its Applications in Drug Discovery. *Letters in Drug Design & Discovery*. 2024;21(3):480–95.
119. De Vita S, Colarusso E, Chini MG, Bifulco G, Lauro G. PharmaCore: The Automatic Generation of 3D Structure-Based Pharmacophore Models from Protein/Ligand Complexes. *Journal of Chemical Information and Modeling*. 2024;64(10):4263–76.

120. Mustafa YF. Coumarins derived from natural methoxystilbene as oxidative stress-related disease alleviators: Synthesis and in vitro-in silico study. *Journal of Molecular Structure*. 2024;1302:137471.
121. Abdulaziz NT, Mustafa YF. Anticancer properties of hymecromone-derived compounds: A review. *International Journal of Pharmaceutical Research*. 2021;13(1):2163–74.
122. Vitali E, Ficarelli F, Bisson M, Gadioli D, Accordi G, Fatica M, Beccari AR, Palermo G. GPU-optimized approaches to molecular docking-based virtual screening in drug discovery: A comparative analysis. *Journal of Parallel and Distributed Computing*. 2024;186:104819.
123. Paggi JM, Pandit A, Dror RO. The Art and Science of Molecular Docking. *Annual Review of Biochemistry*. 2024;93(1):389–410.
124. Febrina E, Asnawi A. Lead compound discovery using pharmacophore-based models of small-molecule metabolites from human blood as inhibitor cellular entry of SARS-CoV-2. *Journal of Pharmacy & Pharmacognosy Research*. 2023;11(5):810–22.
125. Muhammed MT, Aki-Yalcin E. Homology modeling in drug discovery: Overview, current applications, and future perspectives. *Chemical Biology & Drug Design*. 2019;93(1):12–20.
126. Tang Y, Moretti R, Meiler J. Recent Advances in Automated Structure-Based De Novo Drug Design. *Journal of Chemical Information and Modeling*. 2024;64(6):1794–805.
127. de Sousa NF, de Araújo IMA, Rodrigues TCML, da Silva PR, de Moura JP, Scotti MT, Scotti L. Proposition of In silico Pharmacophore Models for Malaria: A Review. *Combinatorial Chemistry & High Throughput Screening*. 2024;27(17):2525–43.
128. Paulino M, Espinosa-Bustos C, Bertrand J, Cabezas D, Mella J, Dávila B, Cerecetto H, Ballesteros-Casallas A, Salas CO. Development of 3D-QSAR and pharmacophoric models to design new anti- *Trypanosoma cruzi* agents based on 2-aryloxynaphthoquinone scaffold. *SAR and QSAR in Environmental Research*. 2022;33(9):701–28.
129. Dobrachinski L, Ferreira LL, Cirino ME, Andrade-de-Siqueira AI, Mafud AC, Mascarenhas YP, Andricopulo AD, de Moraes J. The 3D pharmacophore modeling to explore new antischistosomal agents among US FDA approved drugs. *Future Medicinal Chemistry*. 2024;16(17):1791–9.
130. Mustafa YF. Combretastatin A4-based coumarins: synthesis, anticancer, oxidative stress-relieving, anti-inflammatory, biosafety, and in silico analysis. *Chemical Papers*. 2024;78:3705–20.
131. Mustafa YF, Bashir MK, Oglah MK, Khalil RR, Mohammed ET. Bioactivity of some natural and semisynthetic coumarin derived compounds. *NeuroQuantology*. 2021;19(6):129–38.
132. Liu X, Shi D, Zhou S, Liu H, Liu H, Yao X. Molecular dynamics simulations and novel drug discovery. *Expert Opinion on Drug Discovery*. 2018;13(1):23–37.
133. Mustafa YF. Classical approaches and their creative advances in the synthesis of coumarins: A brief review. *Journal of Medicinal and Chemical Sciences*. 2021;4(6):612–25.
134. Sakkiah S, Arooj M, Cao GP, Lee KW. Insight the C-Site Pocket Conformational Changes Responsible for Sirtuin 2 Activity Using Molecular Dynamics Simulations. Zheng J, editor. *PLoS ONE*. 2013;8(3):e59278.
135. dos Santos Nascimento IJ, de Moura RO. Molecular Dynamics Simulations in Drug Discovery. *Mini-Reviews in Medicinal Chemistry*. 2024;24(11):1061–2.
136. Mustafa YF, Khalil RR, Mohammed ET. Synthesis and antitumor potential of new 7-halocoumarin-4-acetic acid derivatives. *Egyptian Journal of Chemistry*. 2021;64(7):3711–6.
137. Haris NIN, Sobri S, Yusof YA, Kassim NK. An Overview of Molecular Dynamic Simulation for Corrosion Inhibition of Ferrous Metals. *Metals*. 2020;11(1):46.
138. Mustafa YF, Najem MA, Tawffiq ZS. Coumarins from Creston apple seeds: Isolation, chemical modification, and cytotoxicity study. *Journal of Applied Pharmaceutical Science*. 2018;8(8):49–56.
139. Garduño-Juárez R, Tovar-Anaya DO, Perez-Aguilar JM, Lozano-Aguirre Beltran LF, Zubillaga RA, Alvarez-Perez MA, Villarreal-Ramirez E. Molecular Dynamic Simulations for Biopolymers with Biomedical Applications. *Polymers*. 2024;16(13):1864.
140. Mustafa YF. Synthesis, characterization and preliminary cytotoxic study of sinapic acid and its analogues. *Journal of Global Pharma Technology*. 2019;11(9):1–10.
141. Jasim MHM, Mustafa YF. Synthesis of Acetaminophen-Based Coumarins as Selective COX-2 Inhibitors: An in vitro-in silico Study. *Chemistry & Biodiversity*. 2024;21(10):e202401309.
142. Mahmood AAJ, Mustafa YF, Abdulstaar M. New coumarinic azo-derivatives of metoclopramide and diphenhydramine: Synthesis and in vitro testing for cholinesterase inhibitory effect and protection ability against chlorpyrifos. *International Medical Journal Malaysia*. 2014;13(1):3–12.
143. Gkeka P, Stoltz G, Barati Farimani A, Belkacemi Z, Ceriotti M, Chodera JD, Dinner AR, Ferguson AL, Maillet JB, Minoux H, Peter C, Pietrucci F, Silveira A, Tkatchenko A, Trstanova Z, Wiewiora R, Lelièvre T. Machine Learning Force Fields and Coarse-Grained Variables in Molecular Dynamics: Application to Materials and Biological Systems. *Journal of Chemical Theory and Computation*. 2020;16(8):4757–75.
144. Mustafa YF, Abdulaziz NT. Hymecromone and its products as cytotoxic candidates for brain cancer : A brief review. *NeuroQuantology*. 2021;19(7):175–86.
145. Zeki NM, Mustafa YF. Synthesis of Novel Dioxathiole-6,7-coumarin Hybrids As Cytosafe-Multifunctional Applicants: An In Vitro—In Silico Study. *Russian Journal of Bioorganic Chemistry*. 2024;50(5):2076–91.

146. Oglah MK, Mustafa YF. Synthesis, antioxidant, and preliminary antitumor activities of new curcumin analogues. *Journal of Global Pharma Technology*. 2020;12(2):854–62.
147. Mahmood AT, Kamal IK, Mustafa YF. Coumarin Backbone as a Door-Opening Key for Investigating Chloroxylenol as Oral Antimicrobial Agents: an In Vitro–In Silico Study. *Russian Journal of Bioorganic Chemistry*. 2024;50(6):2252–68.
148. Mustafa YF. Synthesis, characterization and antibacterial activity of novel heterocycle, coumacine, and two of its derivatives. *Saudi pharmaceutical journal*. 2018;26(6):870–5.
149. Oglah MK, Bashir MK, Mustafa YF, Mohammed ET, Khalil RR. Synthesis and biological activities of 3,5-disubstituted-4-hydroxycinnamic acids linked to a functionalized coumarin. *Systematic Reviews in Pharmacy*. 2020;11(6):717–25.
150. Mustafa YF, Bashir MK, Oglah MK. Original and innovative advances in the synthetic schemes of coumarin-based derivatives: A review. *Systematic Reviews in Pharmacy*. 2020;11(6):598–612.
151. Outeiral C, Strahm M, Shi J, Morris GM, Benjamin SC, Deane CM. The prospects of quantum computing in computational molecular biology. *WIREs Computational Molecular Science*. 2021;11(1).
152. Joshi SY, Deshmukh SA. A review of advancements in coarse-grained molecular dynamics simulations. *Molecular Simulation*. 2021;47(10–11):786–803.
153. Hoffmann F, Mulder FAA, Schäfer L V. Accurate Methyl Group Dynamics in Protein Simulations with AMBER Force Fields. *The Journal of Physical Chemistry B*. 2018;122(19):5038–48.
154. Gallardo A, Bogart BM, Dutagaci B. Protein–Nucleic Acid Interactions for RNA Polymerase II Elongation Factors by Molecular Dynamics Simulations. *Journal of Chemical Information and Modeling*. 2022;62(12):3079–89.
155. Lemkul JA. Introductory Tutorials for Simulating Protein Dynamics with GROMACS. *The Journal of Physical Chemistry B*. 2024;128(39):9418–35.
156. Nian B, Xu YJ, Liu Y. Molecular dynamics simulation for mechanism revelation of the safety and nutrition of lipids and derivatives in food: State of the art. *Food Research International*. 2021;145:110399.
157. Eshtiwi AA, Rathbone DL. A modified bonded model approach for molecular dynamics simulations of New Delhi Metallo- β -lactamase. *Journal of Molecular Graphics and Modelling*. 2023;121:108431.
158. Jung J, Kobayashi C, Kasahara K, Tan C, Kuroda A, Minami K, Ishiduki S, Nishiki T, Inoue H, Ishikawa Y, Feig M, Sugita Y. New parallel computing algorithm of molecular dynamics for extremely huge scale biological systems. *Journal of Computational Chemistry*. 2021;42(4):231–41.
159. Martinez X, Chavent M, Baaden M. Visualizing protein structures — tools and trends. *Biochemical Society Transactions*. 2020;48(2):499–506.
160. Mustafa YF, Mohammed ET, Khalil RR. Synthesis, characterization, and anticoagulant activity of new functionalized biscoumarins. *Egyptian Journal of Chemistry*. 2021;64(8):4461–8.
161. Mustafa YF. Synthesis of 7,8-dihydroxy-4-phenylbenzo[g]coumarins as potential multitarget anti-skin-aging candidates. *Journal of Molecular Structure*. 2025;1321:139806.
162. Mustafa YF, Oglah MK, Bashir MK, Mohammed ET, Khalil RR. Mutual prodrug of 5-ethynyluracil and 5-fluorouracil: Synthesis and pharmacokinetic profile. *Clinical Schizophrenia and Related Psychoses*. 2021;15(5):1–6.
163. Mustafa YF. Coumarins from toxic phenol: An algorithm of their synthesis and assessment as biosafe, wide-spectrum, potent antimicrobial prospects. *Applied Chemical Engineering*. 2024;7(3):5527.
164. Jumintono J, Alkubaisy S, Yáñez Silva D, Singh K, Turki Jalil A, Mutia Syarifah S, Mustafa YF, Mikolaychik I, Morozova L, Derkho M. Effect of cystamine on sperm and antioxidant parameters of ram semen stored at 4 °C for 50 hours. *Archives of Razi Institute*. 2021;76(4):981–9.
165. Mustafa YF, Hassan DA, Faisal AF, Alshaher MM. Synthesis of novel skipped diene-3-halocoumarin conjugates as potent anticancer and antibacterial biocompatible agents. *Results in Chemistry*. 2024;11:101846.
166. Widjaja G, Doewes R iqbal, Rudiansyah M, Sultan MQ, Ansari MJ, Izzat SE, Al Jaber MS, Kzar HH, Mustafa YF, Hammid AT, Turki Jalil A, Aravindhyan S. Effect of tomato consumption on inflammatory markers in health and disease status: A systematic review and meta-analysis of clinical trials. *Clinical Nutrition ESPEN*. 2022;50:93–100.
167. Li DD, Wu TT, Yu P, Wang ZZ, Xiao W, Jiang Y, Zhao LG. Molecular Dynamics Analysis of Binding Sites of Epidermal Growth Factor Receptor Kinase Inhibitors. *ACS Omega*. 2020;5(26):16307–14.
168. da Fonseca AM, Caluaco BJ, Madureira JMC, Cabongo SQ, Gaieta EM, Djata F, Colares RP, Neto MM, Fernandes CFC, Marinho GS, dos Santos HS, Marinho ES. Screening of Potential Inhibitors Targeting the Main Protease Structure of SARS-CoV-2 via Molecular Docking, and Approach with Molecular Dynamics, RMSD, RMSF, H-Bond, SASA and MMGBSA. *Molecular Biotechnology*. 2024;66(8):1919–33.
169. Thangapandian S, John S, Arooj M, Lee KW. Molecular Dynamics Simulation Study and Hybrid Pharmacophore Model Development in Human LTA4H Inhibitor Design. Zheng J, editor. *PLoS ONE*. 2012;7(4):e34593.
170. De P, Kar S, Ambure P, Roy K. Prediction reliability of QSAR models: an overview of various validation tools. *Archives of Toxicology*. 2022;96(5):1279–95.
171. Atia YA, Bokov DO, Zinnatullovič KR, Kadhim MM, Suksatan W, Abdelbasset WK, Hammoodi HA, Mustafa YF, Cao Y. The role of amino acid functionalization for improvement of adsorption Thioguanine anticancer drugs on the boron nitride nanotubes for drug delivery. *Materials Chemistry and Physics*. 2022;278:125664.
172. Kamal IK, Mahmood AT, Mustafa YF. Synthesis of Eugenol-Derived Coumarins as Broad-Spectrum Biosafe Antimicrobial Agents. *Russian Journal of Bioorganic Chemistry*. 2024;50(6):2240–51.

173. Mustafa YF, Kasim SM, Al-Dabbagh BM, Al-Shakarchi W. Synthesis, characterization and biological evaluation of new azo-coumarinic derivatives. *Applied Nanoscience (Switzerland)*. 2023;13:1095–1102.
174. Shah M, Patel M, Shah M, Patel M, Prajapati M. Computational transformation in drug discovery: A comprehensive study on molecular docking and quantitative structure activity relationship (QSAR). *Intelligent Pharmacy*. 2024;2(5):589–95.
175. Rudrapal M, Chetia D. Virtual Screening, Molecular Docking and QSAR Studies in Drug Discovery and Development Programme. *Journal of Drug Delivery and Therapeutics*. 2020;10(4):225–33.
176. Jibroo RN, Mustafa YF, Al-Shakarchi W. Heterocycles fused on a 6,7-coumarin framework: an in-depth review of their structural and pharmacological diversity. *Chemical Papers*. 2024;78:7239–7311.
177. Kasim SM, Abdulaziz NT, Mustafa YF. Synthesis and biomedical activities of coumarins derived from natural phenolic acids. *Journal of Medicinal and Chemical Sciences*. 2022;5(4):546–60.
178. Achary PGR. Applications of Quantitative Structure-Activity Relationships (QSAR) based Virtual Screening in Drug Design: A Review. *Mini-Reviews in Medicinal Chemistry*. 2020;20(14):1375–88.
179. Bdelbasset WAKAA, Asim SAABJ, Harma SAKUS, Argiana RIAM, Okov DMOLB, Baid MAAO, Ussein BAABEDH, Afta HOAL. Alginate-based hydrogels and tubes , as biological macromolecule-based platforms for peripheral nerve tissue engineering : A review. *Annals of Biomedical Engineering*. 2022;
180. Belfield SJ, Firman JW, Enoch SJ, Madden JC, Erik Tollefsen K, Cronin MTD. A review of quantitative structure-activity relationship modelling approaches to predict the toxicity of mixtures. *Computational Toxicology*. 2023;25:100251.
181. Mustafa YF. Modern Developments in the Application and Function of Metal/Metal Oxide Nanocomposite–Based Antibacterial Agents. *BioNanoScience*. 2023;13(2):840–52.
182. Mustafa YF. Synthesis of novel 6-aminocoumarin derivatives as potential–biocompatible antimicrobial and anticancer agents. *Journal of Molecular Structure*. 2025;1320:139658.
183. Mustafa YF, Khalil RR, Mohammed ET, Bashir MK, Oglah MK. Effects of structural manipulation on the bioactivity of some coumarin-based products. *Archives of Razi Institute*. 2021;76(5):1297–305.
184. Vijayalakshmi MK, Srinivasan R. Review of Contemporary QSAR Study Approach. *Chemistry Africa*. 2024;7(6):2963–73.
185. Mustafa YF. Synthesis, characterization, and biomedical assessment of novel bisimidazole–coumarin conjugates. *Applied Nanoscience (Switzerland)*. 2023;13(3):1907–18.
186. Mustafa YF. 3-mercaptocoumarins as potential bioactive candidates: From novel synthesis to comparative analysis. *Journal of Molecular Structure*. 2025;1320:139657.
187. Mohammed ET, Mustafa YF. Coumarins from red delicious apple seeds: Extraction, phytochemical analysis, and evaluation as antimicrobial agents. *Systematic Reviews in Pharmacy*. 2020;11(2):64–70.
188. Jibroo RN, Mustafa YF. Linearly ring-fused coumarins: A review of their cancer-fighting attributes. *Results in Chemistry*. 2024;8:101611.
189. Khalil RR, Mustafa YF. Phytochemical, antioxidant and antitumor studies of coumarins extracted from Granny Smith apple seeds by different methods. *Systematic Reviews in Pharmacy*. 2020;11(2):57–63.
190. Muratov EN, Bajorath J, Sheridan RP, Tetko I V., Filimonov D, Poroikov V, Oprea TI, Baskin II, Varnek A, Roitberg A, Isayev O, Curtalolo S, Fourches D, Cohen Y, Aspuru-Guzik A, Winkler DA, Agrafiotis D, Cherkasov A, et al. QSAR without borders. *Chemical Society Reviews*. 2020;49(11):3525–64.
191. Jebir RM, Mustafa YF. Novel coumarins isolated from the seeds of *Citrullus lanatus* as potential antimicrobial agents. *Eurasian Chemical Communications*. 2022;4(8):692–708.
192. Rohmah MK, Salahdin OD, Gupta R, Muzammil K, Qasim MT, Al-qaim ZH, Abbas NF, Jawad MA, Yasin G, Mustafa YF, Heidary A, Abarghouei S. Modulatory role of dietary curcumin and resveratrol on growth performance, serum immunity responses, mucus enzymes activity, antioxidant capacity and serum and mucus biochemicals in the common carp, *Cyprinus carpio* exposed to abamectin. *Fish and Shellfish Immunology*. 2022;129:221–30.
193. Mustafa YF. Emerging trends and future opportunities for coumarin-heterocycle conjugates as antibacterial agents. *Results in Chemistry*. 2023;6:101151.
194. Zamanian MY, Parra RMR, Soltani A, Kujawska M, Mustafa YF, Raheem G, Al-Awsi L, Lafta HA, Taheri N, Heidari M, Golmohammadi M, Bazmandegan G. Targeting Nrf2 signaling pathway and oxidative stress by resveratrol for Parkinson’s disease: an overview and update on new developments. *Molecular Biology Reports*. 2023;50:5455–5464.
195. Waheed SA, Mustafa YF. Synthesis and Evaluation of New Coumarins as Antitumor and Antioxidant Applicants. *Journal of Medicinal and Chemical Sciences*. 2022;5(5):808–19.
196. Budi HS, Younus LA, Lafta MH, Parveen S, Mohammad HJ, Al-qaim ZH, Jawad MA, Parra RMR, Mustafa YF, Alhachami FR, Karampoor S, Mirzaei R. The role of miR-128 in cancer development, prevention, drug resistance, and immunotherapy. *Frontiers in Oncology*. 2023;12:1067974.
197. Neves BJ, Braga RC, Melo-Filho CC, Moreira-Filho JT, Muratov EN, Andrade CH. QSAR-Based Virtual Screening: Advances and Applications in Drug Discovery. *Frontiers in Pharmacology*. 2018;9.

198. Patel HM, Noolvi MN, Sharma P, Jaiswal V, Bansal S, Lohan S, Kumar SS, Abbot V, Dhiman S, Bhardwaj V. Quantitative structure–activity relationship (QSAR) studies as strategic approach in drug discovery. *Medicinal Chemistry Research*. 2014;23(12):4991–5007.
199. Sahu SK, Ojha KK. Applications of QSAR study in drug design of tubulin binding inhibitors. *Journal of Biomolecular Structure and Dynamics*. 2024;42(23):12806–21.
200. Al-Nima RRO, Al-Askari AWH, Othman KMZ, Eesee AK. Enhancing Finger Outer Knuckles Recognition Using Deep Recurrent Neural Network. *Journal of Engineering Science and Technology*. 2023;18(6):2915–27.
201. Budi HS, Jameel MF, Widjaja G, Alasady MS, Mahmudiono T, Mustafa YF, Fardeeva I, Kuznetsova M. Study on the role of nano antibacterial materials in orthodontics (a review). *Brazilian Journal of Biology*. 2024;84:e257070.
202. Kolluri S, Lin J, Liu R, Zhang Y, Zhang W. Machine Learning and Artificial Intelligence in Pharmaceutical Research and Development: a Review. *The AAPS Journal*. 2022;24(1):19.
203. Khalil RR, Mohammed ET, Mustafa YF. Various promising biological effects of Cranberry extract : A review. *Clinical Schizophrenia and Related Psychoses*. 2021;15(S6):1–9.
204. Gupta R, Srivastava D, Sahu M, Tiwari S, Ambasta RK, Kumar P. Artificial intelligence to deep learning: machine intelligence approach for drug discovery. *Molecular Diversity*. 2021;25(3):1315–60.
205. Abdulaziz NT, Mohammed ET, Khalil RR, Mustafa YF. Unrevealing the total phenols, total flavonoids, antioxidant, anti-inflammatory, and cytotoxic effects of Garden Cress seed ethanolic extracts. *Review of Clinical Pharmacology and Pharmacokinetics - International Edition*. 2024;38(2):187–96.
206. von Lilienfeld OA, Burke K. Retrospective on a decade of machine learning for chemical discovery. *Nature Communications*. 2020;11(1):4895.
207. Patel V, Shah M. Artificial intelligence and machine learning in drug discovery and development. *Intelligent Medicine*. 2022;2(3):134–40.
208. Bloh A hameed, Khamis MF, Altekreyt AAA, Mustafa YF, Almashhadani HA, Kadhim MM. Total Oxidants, Lipid Peroxidation and Antioxidant Capacity in the Serum of Rheumatoid Arthritis Patients. *Journal of Pharmaceutical Negative Results*. 2022;13(3):231–5.
209. Keyvanpour MR, Shirzad MB. An Analysis of QSAR Research Based on Machine Learning Concepts. *Current Drug Discovery Technologies*. 2021;18(1):17–30.
210. Zeki NM, Mustafa YF. Digital alchemy: Exploring the pharmacokinetic and toxicity profiles of selected coumarin-heterocycle hybrids. *Results in Chemistry*. 2024;10:101754.
211. Patel L, Shukla T, Huang X, Ussery DW, Wang S. Machine Learning Methods in Drug Discovery. *Molecules*. 2020;25(22):5277.
212. Obaido G, Mienye ID, Egbelowo OF, Emmanuel ID, Ogunleye A, Ogbuokiri B, Mienye P, Aruleba K. Supervised machine learning in drug discovery and development: Algorithms, applications, challenges, and prospects. *Machine Learning with Applications*. 2024;17:100576.
213. Polanski J. Unsupervised Learning in Drug Design from Self-Organization to Deep Chemistry. *International Journal of Molecular Sciences*. 2022;23(5):2797.
214. Tan RK, Liu Y, Xie L. Reinforcement learning for systems pharmacology-oriented and personalized drug design. *Expert Opinion on Drug Discovery*. 2022;17(8):849–63.
215. Jebir RM, Mustafa YF. Natural products catalog of allsweet watermelon seeds and evaluation of their novel coumarins as antimicrobial candidates. *Journal of Medicinal and Chemical Sciences*. 2022;5(5):831–47.
216. Waheed SA, Mustafa YF. Novel naphthalene-derived coumarin composites: synthesis, antibacterial, and antifungal activity assessments. *Eurasian Chemical Communications*. 2022;4(8):709–24.
217. Hussain W, Rasool N, Khan YD. Insights into Machine Learning-based Approaches for Virtual Screening in Drug Discovery: Existing Strategies and Streamlining Through FP-CADD. *Current Drug Discovery Technologies*. 2021;18(4):463–72.
218. Arul Murugan N, Ruba Priya G, Narahari Sastry G, Markidis S. Artificial intelligence in virtual screening: Models versus experiments. *Drug Discovery Today*. 2022;27(7):1913–23.
219. Maashi MS, Al-Mualm M, Al-Awsi GRL, Opulencia MJC, Al-Gazally ME, Abdullaev B, Abdelbasset WK, Ansari MJ, Jalil AT, Alsaikhan F, Shalaby MN, Mustafa YF. Apigenin alleviates resistance to doxorubicin in breast cancer cells by acting on the JAK/STAT signaling pathway. *Molecular Biology Reports*. 2022;49:8777–84.
220. Abdelbasset WK, Elkhali SM, Ismail KA, AL-Ghamdi HS, Mironov S, Ridha HSH, Maashi MS, Thangavelu L, Mahmudiono T, Mustafa YF. Mequinol-loaded carboxymethyl cellulose/chitosan electrospun wound dressing as a potential candidate to treat diabetic wounds. *Cellulose*. 2022;29(14):7863–81.
221. Moshawih S, Goh HP, Kifli N, Idris AC, Yassin H, Kotra V, Goh KW, Liew K Bin, Ming LC. Synergy between machine learning and natural products cheminformatics: Application to the lead discovery of anthraquinone derivatives. *Chemical Biology & Drug Design*. 2022;100(2):185–217.
222. Chen Y, Kirchmair J. Cheminformatics in Natural Product-based Drug Discovery. *Molecular Informatics*. 2020;39(12).
223. Zeki NM, Mustafa YF. 6,7-Coumarin-heterocyclic hybrids: A comprehensive review of their natural sources, synthetic approaches, and bioactivity. *Journal of Molecular Structure*. 2024;1303:137601.

224. Lin X, Li X, Lin X. A Review on Applications of Computational Methods in Drug Screening and Design. *Molecules*. 2020;25(6):1375.
225. Kalita P, Tripathi T, Padhi AK. Computational Protein Design for COVID-19 Research and Emerging Therapeutics. *ACS Central Science*. 2023;9(4):602–13.
226. Arooj M, Shehadi I, Nassab CN, Mohamed AA. Computational insights into binding mechanism of drugs as potential inhibitors against SARS-CoV-2 targets. *Chemical Papers*. 2022;76(1):111–21.
227. Hassanzadeganroudsari M, Ahmadi A, Rashidi N, Hossain M, Habib A, Apostolopoulos V. Computational Chemistry to Repurposing Drugs for the Control of COVID-19. *Biologics*. 2021;1(2):111–28.
228. Maki J, Oshimura A, Tsukano C, Yanagita RC, Saito Y, Sakakibara Y, Irie K. AI and computational chemistry-accelerated development of an alotaketol analogue with conventional PKC selectivity. *Chemical Communications*. 2022;58(47):6693–6.
229. Muratov EN, Amaro R, Andrade CH, Brown N, Ekins S, Fourches D, Isayev O, Kozakov D, Medina-Franco JL, Merz KM, Oprea TI, Poroikov V, Schneider G, Todd MH, Varnek A, Winkler DA, Zakharov A V., Cherkasov A, et al. A critical overview of computational approaches employed for COVID-19 drug discovery. *Chemical Society Reviews*. 2021;50(16):9121–51.
230. Baum ZJ, Yu X, Ayala PY, Zhao Y, Watkins SP, Zhou Q. Artificial Intelligence in Chemistry: Current Trends and Future Directions. *Journal of Chemical Information and Modeling*. 2021;61(7):3197–212.
231. Khodadadi E, Maroufi P, Khodadadi E, Esposito I, Ganbarov K, Esposito S, Yousefi M, Zeinalzadeh E, Kafil HS. Study of combining virtual screening and antiviral treatments of the Sars-CoV-2 (Covid-19). *Microbial Pathogenesis*. 2020;146:104241.
232. Zeki NM, Mustafa YF. Synthesis and evaluation of novel ring-conjugated coumarins as biosafe broad-spectrum antimicrobial candidates. *Journal of Molecular Structure*. 2024;1309:138192.
233. Zeki NM, Mustafa YF. Annulated Heterocyclic[g]Coumarin Composites: Synthetic Approaches and Bioactive Profiling. *Chemistry & Biodiversity*. 2023;e202301855.
234. Shahrajabian MH, Sun W, Cheng Q. The Importance of Flavonoids and Phytochemicals of Medicinal Plants with Antiviral Activities. *Mini-Reviews in Organic Chemistry*. 2022;19(3):293–318.
235. Faisal S, Badshah SL, Kubra B, Emwas AH, Jaremko M. Alkaloids as potential antivirals. A comprehensive review. *Natural Products and Bioprospecting*. 2023;13(1):4.
236. Bhattacharjee AK. A review on recent theoretical approaches made in the discovery of potential Covid-19 therapeutics. *Journal of Mathematical Chemistry*. 2024;62(10):2924–42.
237. Strianese O, Rizzo F, Ciccarelli M, Galasso G, D'Agostino Y, Salvati A, Del Giudice C, Tesorio P, Rusciano MR. Precision and Personalized Medicine: How Genomic Approach Improves the Management of Cardiovascular and Neurodegenerative Disease. *Genes*. 2020;11(7):747.
238. Yamamoto Y, Kanayama N, Nakayama Y, Matsushima N. Current Status, Issues and Future Prospects of Personalized Medicine for Each Disease. *Journal of Personalized Medicine*. 2022;12(3):444.
239. Mustafa YF. Biocompatible chlorocoumarins from harmful chlorophenols, their synthesis and biomedical evaluation. *Journal of Molecular Structure*. 2024;1309:138193.
240. Mustafa YF. New Coumarin-Metronidazole Composites: Synthesis, Biocompatibility, and Anti-anaerobic Bacterial Activity. *Russian Journal of Bioorganic Chemistry*. 2024;50(1):201–10.
241. Serrano DR, Luciano FC, Anaya BJ, Ongoren B, Kara A, Molina G, Ramirez BI, Sánchez-Guirales SA, Simon JA, Tomietto G, Rapti C, Ruiz HK, Rawat S, Kumar D, Lalatsa A. Artificial Intelligence (AI) Applications in Drug Discovery and Drug Delivery: Revolutionizing Personalized Medicine. *Pharmaceutics*. 2024;16(10):1328.
242. Moingeon P, Kuenemann M, Guedj M. Artificial intelligence-enhanced drug design and development: Toward a computational precision medicine. *Drug Discovery Today*. 2022;27(1):215–22.
243. Scafuri B, Verdino A, D'Arminio N, Marabotti A. Computational methods to assist in the discovery of pharmacological chaperones for rare diseases. *Briefings in Bioinformatics*. 2022;23(5).
244. Ma C, Gurkan-Cavusoglu E. A comprehensive review of computational cell cycle models in guiding cancer treatment strategies. *npj Systems Biology and Applications*. 2024;10(1):71.
245. Chunarkar-Patil P, Kaleem M, Mishra R, Ray S, Ahmad A, Verma D, Bhayye S, Dubey R, Singh H, Kumar S. Anticancer Drug Discovery Based on Natural Products: From Computational Approaches to Clinical Studies. *Biomedicines*. 2024;12(1):201.
246. Dalbanjan NP, Praveen Kumar SK. A Chronicle Review of In-Silico Approaches for Discovering Novel Antimicrobial Agents to Combat Antimicrobial Resistance. *Indian Journal of Microbiology*. 2024;64(3):879–93.
247. Abramov YA, Sun G, Zeng Q. Emerging Landscape of Computational Modeling in Pharmaceutical Development. *Journal of Chemical Information and Modeling*. 2022;62(5):1160–71.
248. Landauer R. Fundamental Limitations in the Computational Process. *Berichte der Bunsengesellschaft für physikalische Chemie*. 1976;80(11):1048–59.
249. Hadi Prayogo Y, Tri Wahyudi S, Batubara I, Kartika Sari R, Syafii W. Multitarget Ensemble Docking of Potent Anticancer and Antioxidant Active Compounds from the *Acacia auriculiformis* and *Acacia crassicarpa*. *Research Journal of Pharmacy and Technology*. 2024;707–16.
250. Fan M, Wang J, Jiang H, Feng Y, Mahdavi M, Madduri K, Kandemir MT, Dokholyan N V. GPU-Accelerated Flexible Molecular Docking. *The Journal of Physical Chemistry B*. 2021;125(4):1049–60.

251. Zhu X, Sedykh A, Liu S. Hybrid in silico models for drug-induced liver injury using chemical descriptors and in vitro cell-imaging information. *Journal of Applied Toxicology*. 2014;34(3):281–8.
252. Chen T. Artificial Intelligence and Drug Design: Future Prospects and Ethical Considerations. *Computational Molecular Biology*. 2024;
253. DoCarmo T, Rea S, Conaway E, Emery J, Raval N. The law in computation: What machine learning, artificial intelligence, and big data mean for law and society scholarship. *Law & Policy*. 2021;43(2):170–99.